Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million

.m. on 1 August 2012, (or such later date as agreed by the Company).

Convertible Loan Note

The Company also announces today the conditional issue of a £1 million Convertible Loan Note to Robert Keith.  The principal terms of the Convertible Loan Note are:

  • repayment on 1 August 2019, seven years after issue, if not previously converted into Ordinary Shares;
  • convertible into newly issued Ordinary Shares at the Issue Price;
  • convertible at any time from issue to maturity.

The price at which the Convertible Loan Note will convert into Ordinary Shares is subject to adjustment in certain circumstances.  The Convertible Loan Note is secured by way of a pledge by the Company over the entire issued share capital of Silence AG and by a pledge by Silence AG of certain intellectual property rights owned by Silence AG.

In addition to the Convertible Loan Note, the Company has conditionally granted warrants over 7,500,000 Ordinary Shares, to ISM Capital pursuant to the CL Warrant.  The warrants will be exercisable at a price of 1 pence at any time prior to the expiry of 36 months from the date of the CL Warrant.

The Convertible Loan Note and the CL Warrant are conditional, inter alia, upon the passing of Resolutions 1 to 3 and 8 and 9 (as set out in the Notice of General Meeting), the Share Capital Reorganisation occurring  and Admission of the New Ordinary Shares.

Establishment of an Equity Finance Facility

The EFF provides Silence with a £10 million facility which (subject to certain limited restrictions) can be drawn down at any time over the next three years. The timing and value of any draw down is at the sole discretion of the Company.

Silence is under no obligation to make a draw down.  The Company may make draw downs up to the total value of the EFF by way of issuing subscription notices to

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
(Date:1/15/2014)... 2014 This webinar will focus on ... safety assessment in biosimilars. , Regulatory frameworks are evolving ... development, however the complex nature of biopharmaceuticals makes the ... efficacy extremely challenging. Based on the specific aspects of ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... and Brent Butler 2 , ... Massachusetts, USA , ... , Introduction , ... carried out using manual pipetting. As the demand for greater throughput of plate ...
... , , , , FLEXSTATION IS A ... SIMPLE, RAPID EXPERIMENTAL SET-UP AND DATA ANALYSIS , , ... , EXCELLENT FOR ASSAY DEVELOP-MENT AS DEMONSTRATED BY Z FACTOR ... G q -coupled receptors are transmembrane proteins that are responsible ...
... , HOMOGENEOUS ASSAY , , ... PROCEDURE , , COMPATIBLE WITH MORE TARGETS ... , The ... detecting changes,in intracellular calcium concentration.,Specifically, this fast and simple fluorescencebased,assay allows the ...
Cached Biology Technology:96 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 296 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 396 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 4Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor 2Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor 3Gq-coupled receptor assays using FLEXstation: M1 muscarinic receptor 4Calcium Plus Assay Kit, Superior Detection for Specialized Targets 2Calcium Plus Assay Kit, Superior Detection for Specialized Targets 3
(Date:4/23/2014)... of Public Health-Bloomington has bolstered the link between red ... association between heme iron, found only in meat, and ... that heme iron consumption increased the risk for coronary ... found between nonheme iron, which is in plant and ... study was published online ahead of print in the ...
(Date:4/23/2014)... Toronto Scarborough research shows that male black widow spiders ... a rare example of mate preference by male spiders. ... Emily MacLeod and Maydianne Andrade, a professor in UTSC,s ... studies and the wild that males overwhelmingly chose to ... black widows can tell whether a potential mate is ...
(Date:4/23/2014)... the likelihood of an accurate group decision increases with ... when a collective faces a variety of factors ... University researchers report that smaller groups actually tend to ... excessively focused on only certain pieces of information. , ... known about collective intelligence, or the "wisdom of crowds," ...
Breaking Biology News(10 mins):Study: Iron consumption can increase risk for heart disease 2Picky male black widow spiders prefer well-fed virgins 2Too many chefs: Smaller groups exhibit more accurate decision-making 2Too many chefs: Smaller groups exhibit more accurate decision-making 3
... Va. The availability of new genome sequencing ... to test an intriguing hypothesis about how agricultures ... plant pathogens. Boris Vinatzer, assistant professor of ... College of Agriculture and Life Sciences, has received ...
... GAINESVILLE, Fla. Using the genetic equivalent of an ... the Earth endured a massive cooling period between 500 ... (Feb. 7) in the journal Nature, researchers from the ... and the biotechnology company DNA2.0 describe how they reconstructed ...
... YORK (FEBRUARY 7, 2008) Madagascars turtles and tortoises, ... will continue to crawl steadily toward extinction unless major ... by the Wildlife Conservation Society and other groups. ... capital city Antananarivo, said there is still hope to ...
Cached Biology News:Tomato pathogen genome may offer clues about bacterial evolution at dawn of agriculture 2Scientists rebuild ancient proteins to reveal primordial Earth's temperature 2Madagascar's tortoises are crawling toward extinction, groups say 2
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
... OrientExpress™ System Modules ... synthesis and directional cloning ... T7 expression vectors ... configuring OrientExpress™ Cloning Systems, ...
... and antibody-based immunoaffinity matrices, such as ... times without compromising antigen-antibody reactivity, the ... agents has precluded the application of ... The CHEMICON Re-Blot Plus Western Blot ...
Biology Products: